Poltronesofà outlines UK progress to date
Poltronesofà UK (A Share & Sons, formerly ScS), says its Italian parent group’s vision and strategy have now…
AIM ImmunoTech Reports Positive Mid-Year Interim Clinical Progress from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer
Company remains on track for a planned December 2026 evaluation of the clinical trial’s primary endpoint OCALA, Fla.,…